Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talazoparib and Temozolomide in Relapsed/Refractory Extensive-Stage SCLC
NCT03672773Phase 2Active, not recruiting
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Oct 2018
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of talazoparib in small cell lung cancer (SCLC), sponsored by UCLA Jonsson Comprehensive Cancer Center. Started Oct 2018; status: active, not recruiting.
02
Drugs
talazoparib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT03672773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03672773.